Effectiveness of duloxetine for the treatment of chronic nonorganic orofacial pain

Clinical Neuropharmacology

Volumn 35, Issue 6, 2012, Pages 273-277

  Nagashima, Wataru ^a   Kimura, Hiroyuki ^a   Ito, Mikiko ^b   Tokura, Tatsuya ^a   Arao, Munetaka ^b   Aleksic, Branko ^a   Yoshida, Keizo ^c   Kurita, Kenichi ^b   Ozaki, Norio ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c DENSO CORPORATION   (Japan)

Author keywords

atypical odontalgia; burning mouth syndrome; chronic pain; duloxetine, serotonin noradrenaline reuptake inhibitor

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; BROTIZOLAM; DULOXETINE; FLUVOXAMINE; MILNACIPRAN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANXIETY DISORDER; ARTICLE; BURNING MOUTH SYNDROME; CHRONIC NONORGANIC OROFACIAL PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MALE; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; SOMNOLENCE; SYMPTOMATOLOGY; TOOTH PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION; VISUAL ANALOG SCALE; VOMITING; XEROSTOMIA;

AGED; ANTIDEPRESSIVE AGENTS; CHRONIC PAIN; FACIAL PAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; THIOPHENES; TREATMENT OUTCOME;

EID: 84870053377     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31827453fa     Document Type: Article

References (33)

1. Reid KJ, Harker J, Bala MM, et al. Epidemiology of chronic non-cancer pain in Europe: narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011;27:449-462.
2. Zakrzewska JM, Forssell H, Glenny AM. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev 2005; (1): CD002779. DOI:10.1002/14651858. CD002779.pub2.
3. Melis M, Lobo SL, Cenevis C, et al. Atypical odontalgia: a review of the literature. Headache 2003;43:1060-1074. (Pubitemid 37543073)
4. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009;31:206-219.
5. Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234-241. (Pubitemid 38314873)
6. Hindmarch I, Rigney U, Stanley N, et al. Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol 2000;49:118-125. (Pubitemid 30068289)
7. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-880. (Pubitemid 34031892)
8. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15. (Pubitemid 41752960)
9. Häuser W, Bernardy K, Uçeyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009;301:198-209.
10. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009; (4): CD007115. DOI:10.1002/14651858. CD007115.pub2.
11. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118. (Pubitemid 40828506)
12. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-1420. (Pubitemid 44632065)
13. Ito M, Kimura H, Yoshida K, et al. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol 2010;33:79-83.
14. Ikawa M, Yamada K, Ikeuchi S. Efficacy of amitriptyline for treatment of somatoform pain disorder in the orofacial region: a case series. J Orofac Pain 2006;20:234-240. (Pubitemid 44265211)
15. Pinto A, Sollecito TP, DeRossi SS. Burning mouth syndrome. 1A retrospective analysis of clinical characteristics and treatment outcomes. N Y State Dent J 2003;69:18-24.
16. Kimura H, Yoshida K, Ito M, et al. Plasma levels of milnacipran and its effectiveness for the treatment of chronic pain in the orofacial region. Hum Psychopharmacol Clin Exp 2012;27:322-328.
17. Mignogna MD, Adamo D, Schiavone V, et al. Burning mouth syndrome responsive to duloxetine: a case report. Pain Med 2011;12:466-469.
18. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-2445. (Pubitemid 37385786)
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington DC: APA; 2000.
20. Urdan TC. Repeated-measures analysis of variance. In: Statistics in Plain English. 2nd ed. Mahwah: Lawrence Erlbaum Associates; 2005:129-144.
21. *Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-191.
22. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
23. Mico JA, Ardid D, Berrocoso E, et al. Antidepressants and pain. Trends Pharmacol Sci 2006;27:348-354. (Pubitemid 43963184)
24. Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474. (Pubitemid 34606906)
25. Iyengar S, Webster AA, Hemrick-Luecke SK, et al. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-584. (Pubitemid 39391542)
26. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010;11:505-521.
27. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39-47. (Pubitemid 36070863)
28. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-909. (Pubitemid 46972905)
29. Wright A, Luedtke KE, Vandenberg C. Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy. J Pain Res 2010;4:1-10.
30. Choy EH, Mease PJ, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol 2009;28:1035-1044.
31. Hall JA, Wang F, Oakes TM, et al. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Expert Opin Drug Saf 2010;9:525-537.
32. Bellingham GA, Peng PW. Duloxetine: a review of its pharmacology and use in chronic pain management. Reg Anesth Pain Med 2010;35:294-303.
33. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-197. (Pubitemid 18029372)